Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 18/20 | 0.80 |
| ▸ | CCND1 | P24385 | 16/20 | 0.80 |
| ▸ | CDK6 | Q00534 | 12/20 | 0.80 |
| ▸ | CCND3 | P30281 | 4/20 | 0.80 |
| ▸ | CDK2 | P24941 | 3/20 | 0.80 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.80 |
| ▸ | GAK | O14976 | 1/20 | 0.80 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.80 |
| ▸ | FECH | P22830 | 1/20 | 0.80 |
| ▸ | CDK9 | P50750 | 1/20 | 0.80 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.80 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.80 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.80 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.80 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.80 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.80 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.80 |
| ▸ | CDK1 | P06493 | 1/20 | 0.77 |
| ▸ | CCND2 | P30279 | 3/20 | 0.73 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31121782 | 1.00 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL29507623 | 1.00 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| Dimethylamine SCHEMBL28726027 | 0.92 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL23837859 | 0.91 | CDK4 (0.83) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL29507453 | 0.91 | CDK4 (0.81) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL2685016 | 0.91 | CDK4 (0.81) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL2362403 | 0.90 | CDK4 (0.76) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL20980374 | 0.90 | CDK4 (0.68) | CDK4CCND1CDK6CCND3CDK2 | |
| Ribociclib SCHEMBL302310 | 0.89 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CDK2 | |
| Ribociclib SCHEMBL29384231 | 0.89 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | claimed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | claimed |
| US-20170183352-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | claimed |
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | claimed |
| JP-2012500785-A | — | — | 2012-01-12 | — | — | JP | claimed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | claimed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | claimed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | claimed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | claimed |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
| US-20230118053-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2021-08-19 | — | — | US | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | CDK4, CDK6, CDK8 | CDK4 1/4885CCND1 44/4885CDK6 2/4885 |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | CDK4 10/4885CCND1 57/4885CDK6 2/4885 |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CDK4 5/4885CCND1 46/4885CDK6 1/4885 |
| US-20230118053-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | CDK6, CDK4, CDK2 | CDK4 2/4885CCND1 55/4885CDK6 1/4885 |
| US-20170183352-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CDK4 5/4885CCND1 46/4885CDK6 1/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CDK4 5/4885CCND1 46/4885CDK6 1/4885 |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CDK4 5/4885CCND1 46/4885CDK6 1/4885 |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CDK4 5/4885CCND1 46/4885CDK6 1/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | CDK4 5/4885CCND1 46/4885CDK6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.